FDA Cites Two Aurobindo Facilities for Serious GMP Violations
The FDA hit two Aurobindo facilities for serious violations of good manufacturing practices discovered during inspections in October.
Source: Drug Industry Daily
The FDA hit two Aurobindo facilities for serious violations of good manufacturing practices discovered during inspections in October.
Source: Drug Industry Daily